International Conferences

Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer


Recommended Conferences for Systemic Sclerosis

Systemic Sclerosis

As per available reports about 12 Conferences, are presently dedicated exclusively to Systemic Sclerosis

Systemic scleroderma is an autoimmune or connective tissues disease. It is characterized by thickening of the skin caused by accumulation of collagen, and by injuries to the smallest arteries. There are two overlapping forms. Limited cutaneous scleroderma is limited to the skin on the face, hands and feet. Diffuse cutaneous Survival is determined by the severity of visceral disease. Prognosis is difficult to predict until the disease differentiates into recognizable subsets. Patients with limited cutaneous scleroderma have a good prognosis, with 10-year survival of 75%, although <10% develop pulmonary arterial hypertension after 10 to 20 years. Patients with diffuse cutaneous scleroderma have a 10-year survival of 55%. Death is most often from pulmonary, heart and kidney involvement, although survival has greatly improved with effective treatment for kidney failure. Immunosuppressive drugs are used, although glucocorticoids have limited application. Annual incidence is 19 per million, and prevalence is 19-75 per 100,000, with a female: male ratio of 3:1, and 8:1 in mid to late childbearing years. Incidence is twice as high among African Americans, and the Choctaw Native Americans in Oklahoma have the highest prevalence in the world (469/100,000). There is some hereditary association, some suggestion of immune reaction (molecular mimicry) to a virus, and some cases caused by toxins. Diffuse Scleroderma - affects the skin as well as the heart, lungs, GI tract, and kidneys.

OMICS International   Organizes 1000+ Global Events   Every Year across USA, Europe & Asia with support from 1000 more scientific societies   and Publishes 700+ Open access journals  which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The conference series website will provide you list and details about the conference organize worldwide.

Scope and Importance:

Patients with larger amounts of cutaneous involvement are more likely to have involvement of the internal tissues and organs. Most patients (over 80%) have vascular symptoms and Raynaud's phenomenon, which leads to attacks of discoloration of the hands and feet in response to cold. Raynaud's normally affects the fingers and toes. Systemic scleroderma and Raynaud's can cause painful ulcers on the fingers or toes which are known as digital ulcers. Calcinosis (deposition of calcium in lumps under the skin) is also common in systemic scleroderma, and is often seen near the elbows, knees or other joints.Diagnosis is by clinical suspicion, presence of autoantibodies (specifically anti-centromere and anti-scl70/anti-topoisomerase antibodies) and occasionally by biopsy. Of the antibodies, 90% have a detectable anti-nuclear antibody. Anti-centromere antibody is more common in the limited form (80-90%) than in the diffuse form (10%), and anti-scl70 is more common in the diffuse form (30-40%) and in African-American patients (who are more susceptible to the systemic form). 

Limited Scleroderma - mostly affects the skin of the face, neck and distal elbows and knees and late in the disease causes isolated pulmonary hypertension. CREST syndrome (Calcinosis, Raynaud's phenomenon, Esophageal dysfunction, Sclerodactyly, Telangiectasias) is associated with limited scleroderma.There is a slight increase in the risk of cancer with systemic sclerosis.In the skin, systemic sclerosis causes hardening and scarring. The skin may appear tight, reddish or scaly. Blood vessels may also be more visible. Where large areas are affected, fat and muscle wastage may weaken limbs and affect appearance. Also, patients report substantial, even severe and recurrent itching of large skin areas, the source of much affliction as the condition worsens. There is much variation in severity between patients, with some having scleroderma of only a limited area of the skin (such as the fingers) and little involvement of the underlying tissue; while others have progressive skin involvement Diffuse scleroderma can cause musculoskeletal, pulmonary, gastrointestinal, renal and other complications.

One of the suspected mechanisms behind the autoimmune phenomenon is the existence of microchimerism, i.e. fetal cells circulating in maternal blood, triggering an immune reaction to what is perceived as "foreign" material.A distinct form of scleroderma and systemic sclerosis may develop in patients with chronic renal failure. This entity, nephrogenic fibrosing dermopathy or nephrogenic systemic fibrosis, has been linked to the exposure to gadolinium-containing radiocontrast. In 1980 the American College of Rheumatology agreed upon diagnostic criteria for scleroderma. Other conditions may mimic systemic sclerosis by causing hardening of the skin. Diagnostic hints that another disorder is responsible include the absence of Raynaud's phenomenon, a lack of abnormalities in the skin on the hands, a lack of internal organ involvement, and a normal antinuclear antibodies test result. There is no clear obvious cause for scleroderma and systemic sclerosis. Genetic predisposition appears to be limited: genetic concordance is small; still, there often is a familial predisposition for autoimmune disease. Polymorphisms in COL1A2 and TGF-β1 may influence severity and development of the disease. There is limited evidence implicating cytomegalovirus (CMV) as the original epitope of the immune reaction, as well as parvovirus B19.Organic solvents and other chemical agents have been linked with scleroderma. Bleomycin (a chemotherapeutic agent) and possibly taxane chemotherapy may cause scleroderma, and occupational exposure to solvents has been linked with an increased risk of systemic sclerosis. 

Market Analysis:

North America accounted for 62% sales of leukemia drugs in the therapeutics market during 2010 followed by Europe and Asia Pacific. AML therapeutics market will grow and the total growth will depend on pipeline products and metabolic inhibitors, a tyrosine kinase receptor FLT -3 of Novartis and some other capable molecules, improving the therapeutics market.Globally the numbers of elderly people, 60 years and above are growing and it is expected that this age group will cross the 1.3 billion mark in 2017. Hence the acute myeloid leukemia therapeutics market will also grow. Many AML products are in the pipeline or in different clinical phases that will bring the change in disease treatment.

List of Best International Conferences

  1. Cosmetic Dermatology Hair care Conference
    December 07-08, 2015 Philadelphia, USA
  2. 2nd Cosmetic Dermatology Haircare Conference
    December 05-06, 2016 Philadelphia, USA
  3. Allergy Conference
    March 29-30, 2016 Valencia, Spain 
  4. 2nd  Clinical Case Reports
    April 18-20, 2016 Dubai, UAE 
  5. 5th  Cosmetology, Trichology  Aesthetic Practices conference
    April 25-27, 2016 Dubai, UAE.
  6. 6th Clinical & Experimental Dermatology  conference
    May 05-07, 2016 Chicago, USA 
  7. Dermatology conference
    June 13-15, 2016 Alicantae, Spain 
  8. 4th  Acupuncture Therapists Meeting
    July 14-16, 2016 Philadelphia, USA 
  9. 2nd Optometrist Meeting on Laser Technology
    July 28-29, 2016 Berlin, Germany 
  10. 6th  Healthcare Fitness Summit
    August 22-24, 2016 Philadelphia, USA 
  11. 5th Pediatric Congress
    August 25-27, 2016 Sao Paulo, Brazil
  12. Clinical Dermatology Congress
    September 07-09, 2016 Sao Paulo, Brazil 
  13. 2nd Biomedical Engineering Conference
    November 30-December 02, 2015 San Antonio, USA
  14. 3rd Biomedical Engineering Conference
    September 22-23, 2016 Vienna, Austria
  15. Pediatric Dermatology conference
    October 10-12, 2016 Manchester, UK 
  16. 2nd Telemedicine & eHealth  Summit
    October 31-November 2, 2016 Istanbul, Turkey 
  17. 11thdermatologists Meeting
    November 14-16, 2016 Dubai, UAE
  18. Dermatology  Hair care conference
    December 07-08, 2015 Philadelphia, USA
  19. 2nd Dermatology  Hair care conference
    December 05-06, 2016 Philadelphia, USA
  20. 2nd Telemedicine  eHealth  summit
    October 31-November 2, 2016 Istanbul, Turkey 
  21. 11th International congress on systemic lupus erythematosus 2015
    September 2-6, 2015 Austria.
  22. South asian regional dermatology, Leprology and venereology conference
    September 4-6, 2015 Mysuru
  23. 24th European academy of dermaotlogy and venerelogy congress
    October 7-11, 2015 Denmark
  24. 13th Asia pacific environmental and occupational dermatology symposium
    November 4-6, 2015 Manilla
  25. IACD 10th World Congress on cosmetic dermatology
    November 14-16, 2015 Brazil

Relevant Society and Associations:

  • The Scleroderma Society London
  • Scleroderma Foundation 
  • American College of Rheumatology
  • Scleroderma Australia
  • Multiple Sclerosis - Relief
  • Tuberous Sclerosis Association
  • National MS Society
  • Multiple Sclerosis Health
  • Sclerosis society

Relevant Organisation:

  • Yorkshire Neuro Physiotherapy
  • Harrow MS Therapy Centre
  • Glenside
  • Kilbryde Hospice
  • Sutton & Croydon MS Therapy Centre
  • Merlin MS Centre
  • Treetops Hospice
  • The Mary Stevens Hospice
  • Voyage Specialist Healthcare
  • Neuro Partners Ltd 
  • Active Biotech AB 
  • Allergan, Inc. 
  • Angion Biomedica Corp. 
  • arGentis Pharmaceuticals, LLC 
  • Auspex Pharmaceuticals, Inc. 
  • Bayer AG 
  • BioLineRx, Ltd. 
  • Bristol-Myers Squibb Company 
  • Celgene Corporation 
  • Corbus pharmaceuticals, Inc. 
  • Daval International Ltd. 
  • Digna Biotech, S.L. 
  • Dynavax Technologies Corporation 
  • F. Hoffmann-La Roche Ltd. 
  • Fibrocell Science, Inc. 
  • GlaxoSmithKline plc 
  • iBio, Inc. 
  • Inventiva SAS 
  • MedImmune, LLC 
  • NovaLead Pharma Pvt. Ltd. 
  • Vida Therapeutics Inc. 
  • VivaCell Biotechnology Espana S.L.

This page will be updated regularly.

This page was last updated on February 23, 2024

Conference Series Destinations